Matthew Venezia
Stock Analyst at Alliance Global Partners
(0.36)
# 4,493
Out of 5,078 analysts
16
Total ratings
25%
Success rate
-16.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Venezia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VSTM Verastem | Reiterated: Buy | $22 | $10.04 | +119.12% | 1 | Oct 15, 2026 | |
| IMNM Immunome | Initiated Coverage: Buy | $32 | $17.99 | +77.88% | 1 | Sep 21, 2026 | |
| AKTX Akari Therapeutics, | Reiterated: Buy | $20 | $8.23 | +137.08% | 1 | Sep 16, 2026 | |
| MDCX Medicus Pharma | Reiterated: Buy | $50 | $2.50 | +1,900.00% | 1 | Sep 14, 2026 | |
| CAPR Capricor Therapeutics | Reiterated: Hold | n/a | $5.93 | - | 8 | Jul 30, 2026 | |
| NTHI NeOnc Technologies Holdings | Initiated Coverage: Buy | $13 | $3.27 | +297.55% | 1 | May 19, 2026 | |
| PLUR Pluri | Initiated Coverage: Buy | $12 | $0.99 | n/a | 1 | Jun 2, 2025 | |
| CBUS Cibus | Reiterated: Buy | $24 | $1.41 | n/a | 2 | May 9, 2025 |
Verastem
Oct 15, 2026
Reiterated: Buy
Price Target: $22
Current: $10.04
Upside: +119.12%
Immunome
Sep 21, 2026
Initiated Coverage: Buy
Price Target: $32
Current: $17.99
Upside: +77.88%
Akari Therapeutics,
Sep 16, 2026
Reiterated: Buy
Price Target: $20
Current: $8.23
Upside: +137.08%
Medicus Pharma
Sep 14, 2026
Reiterated: Buy
Price Target: $50
Current: $2.50
Upside: +1,900.00%
Capricor Therapeutics
Jul 30, 2026
Reiterated: Hold
Price Target: n/a
Current: $5.93
Upside: -
NeOnc Technologies Holdings
May 19, 2026
Initiated Coverage: Buy
Price Target: $13
Current: $3.27
Upside: +297.55%
Pluri
Jun 2, 2025
Initiated Coverage: Buy
Price Target: $12
Current: $0.99
Upside: n/a
Cibus
May 9, 2025
Reiterated: Buy
Price Target: $24
Current: $1.41
Upside: n/a